Amphera werft eerste patiënten voor fase II studie van MesoPher om alvleesklierkanker te behandelen

Amphera recruits first patients to phase II study of MesoPher to treat pancreatic cancer

Proprietary immuno-oncology approach harnesses autologous dendritic cell therapy
`s-Hertogenbosch, The Netherlands, 21 May 2019. Amphera B.V., an advanced-clinical-stage biotechnology company developing dendritic cell therapies to treat cancer, announces that it has recruited the first patients to a phase II study of MesoPher to treat pancreatic cancer.